Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The adhesive material adheres to biological tissue Photo: Wyss Institute at Harvard University

Inspired by slug secretion properties, scientists and engineers from Harvard have engineered a flexible, medical bandage made out of biomaterials that is able to adhere to wet or bloody wounds without serious side effects, according to a new study published in Science Thursday. The "tough adhesive" (TA) also is strong enough to transfer and dissipate stress, so it can be applied to beating hearts or to skin over joints.

Why this matters: Many current adhesive products are toxic to cells, inflexible when they dry, and do not bind strongly enough to biological tissue especially if the tissue is wet. Scientists have been researching tissue bioadhesives for years, due to the need to promptly control bleeding after trauma or during surgery to avoid severe blood loss in a manner that would also lessen the risk of infection or toxic reaction.

Other uses could be on the internal organs of children since it can stretch as they grow (such as kids with cardiovascular disease) or could be used to attach medical devices to their target structures, such as a pacemaker to support heart function.

Plus: The global market value of all medical adhesives was estimated to be about $5.8 billion in 2013 and is projected to reach $10 billion by 2019, according to MarketsandMarkets Research.

Nature's inspiration: Scientists often study nature's creative ways of dealing with crises to see if there are methods humans can use to adapt for their own use. In this case, the scientists were intrigued by a slug commonly found in Europe and parts of the U.S., called the Dusky Arion. When threatened, this slug produces a special kind of mucus that glues it in place so a predator cannot pry it off its wet or dry surface. "The polymer structure and mechanism of how defensive mucus works provide[d] a general design guideline in developing our material," study author Jianyu Li told Axios.

Yes, but: The TA is not made of slug mucus (as some other organizations may have erroneously stated). The main components of the material are 3 engineered biomaterials, Li said: chitosan derived from shrimp shells, alginate extracted from algae, and a synthetic polymer.

The team used these main ingredients to create a double-layered hydrogel containing positively charged polymers protruding from the surface, which allows it to form a strong bind to biological tissues. The current form is a patch similar to a bandaid but Li said "the design can lead to glue-like adhesive."

Test results: The team tested the material on dry and wet animal tissues, including skin, cartilage, heart, artery and liver. The material was successfully used to seal a hole in a pig heart that was mechanically inflated and deflated and subjected to tens of thousands of cycles of stretching. It stopped liver hemorrhage in mice without causing tissue damage or adhesions to surrounding tissues (common side effects from current adhesives like super glue and commercial thrombin-based adhesive).

"Our work represents a fundamentally new design of tissue adhesives that could achieve superior adhesion performance across various surfaces, even exposed with liquids," Li said. "The surprising finding is that the adhesion has been engineered as strong as one of the toughest soft tissues — articular cartilage."

Ingo Grunwald, a chemist in the Fraunhofer Institute for Manufacturing Technology and Advanced Materials who was not part of this study, told Axios: "Quite significant is the design of the polymer system and its estimated way of reaction. Although the single components are well known, the presented adhesion forces are very good and will open a broader field of application."

Limitations: This has not yet been tested on humans. Li said they have plans to test this form on humans, and research other forms such as a biodegradable form and an injectable adhesive with one-step injection.

Go deeper

Harry and Meghan accuse British royal family of racism

Photo: Joe Pugliese/Harpo Productions via Reuters

Prince Harry and Meghan Markle delivered a devastating indictment of the U.K. royal family in their conservation with Oprah Winfrey: Both said unnamed relatives had expressed concern about what the skin tone of their baby would be. And they accused "the firm" of character assassination and "perpetuating falsehoods."

Why it matters: An institution that thrives on myth now faces harsh reality. The explosive two-hour interview gave an unprecedented, unsparing window into the monarchy: Harry said his father and brother "are trapped," and Markle revealed that the the misery of being a working royal drove her to thoughts of suicide.

Updated 3 hours ago - Axios Twin Cities

In photos: Thousands rally for George Floyd ahead of Derek Chauvin's trial

Demonstrators on March 7 outside the Hennepin County Government Center, where the trial of former Minneapolis police officer Derek Chauvin, charged with murdering George Floyd, will begin in Minneapolis, Minnesota. Photo: Chandan Khanna/AFP via Getty Images

Thousands of protesters marched through Minneapolis' streets Sunday, urging justice for George Floyd on the eve of the start of former police officer Derek Chauvin's trial over the 46-year-old's death, per AFP.

The big picture: Chauvin faces charges for second-degree murder and manslaughter over Floyd's death last May, which ignited massive nationwide and global protests against racism and for police reform. His trial is due to start Monday, with jury selection procedures.

Caitlin Owens, author of Vitals
7 hours ago - Health

Pfizer CEO feels "liberated" after taking COVID vaccine

Pfizer CEO Albert Bourla. Photo: "Axios on HBO"

Pfizer CEO Albert Bourla tells "Axios on HBO" that he recently received his first of two doses of the company's coronavirus vaccine.

Why it matters: Bourla told CNBC in December that company polling found that one of the most effective ways to increase confidence in the vaccine was to have the CEO take it.